Gilead's Lucrative Hep C Patents Face PTAB Assault
A nonprofit group focused on drug competition is attacking six key patents for Gilead Sciences Inc.'s blockbuster portfolio of hepatitis C drugs, telling the Patent Trial and Appeal Board that a...To view the full article, register now.
Already a subscriber? Click here to view full article